NEW YORK (GenomeWeb News) – SynapDx today announced a deal with Illumina aimed at the detection of autism spectrum disorders.

The deal will link SynapDx's autism technologies with Illumina's sequencing platforms to develop tools for the early detection of ASDs, SynapDx said, adding that the companies will also broadly evaluate other opportunities in neurodevelopment.

Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.